Abstract
Get full access to this article
View all access options for this article.
References
1.
Kebebew
E
,
Greenspan
FS
,
Clark
OH
,
Woeber
KA
, McMillan 2005 . Anaplastic thyroid carcinoma: treatment outcome and prognostic factors . Cancer , 103 :1330 –1335 .
2.
Wang
JR
,
Zafereo
ME
,
Dadu
R
,
Ferrarrotto
R
,
Busaidy
NL
,
Lu
C
,
Ahmed
S
,
Gule-Monroe
MK
,
Williams
MD
,
Sturgis
EM
,
Goepfert
RP
,
Gross
ND
,
Lai
SY
,
Brandon Gunn
G
,
Phan
J
,
Rosenthal
DI
,
David Fuller
C
,
Morrison
WH
,
Lyer
P
,
Cabanillas
ME
. 2019 . Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E
-mutated anaplastic thyroid carcinoma . Thyroid , 29 :1036 –1043 .
3.
Pérot
G
,
Soubeyran
I
,
Ribeiro
A
,
Bonhomme
B
,
Savagner
F
,
Boutet-Bouzamondo
N
,
Hostein
I
,
Bonichon
F
,
Godbert
Y
,
Chibon
F
. 2014 . Identification of a recurrent STRN/ALK fusion in thyroid carcinomas . PLoS One , 1 :e87170 .
4.
Godbert
Y
,
Henriques de Figueiredo
B
,
Bonichon
F
,
Chibon
F
,
Hostein
I
,
Pérot
G
,
Dupin
C
,
Daubech
A
,
Belleannée
G
,
Gors
A
,
Italiano
A
,
Soubeyran
I
. 2015 . Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma . J Clin Oncol , 33 :e84 –e87 .
5.
Shaw
AT
,
Kim
DW
,
Mehra
R
,
Tan
DS
,
Felip
E
,
Chow
LQ
,
Camidge
DR
,
Vansteenkiste
J
,
Sharma
S
,
De Pas
T
,
Riely
GJ
,
Solomon
BJ
,
Wolf
J
,
Thomas
M
,
Schuler
M
,
Liu
G
,
Santoro
A
,
Lau
YY
,
Goldwasse
M
,
Boral
AL
,
Engelman
JA
. 2014 . Ceritinib in ALK-rearranged non-small-cell lung cancer . N Engl J Med , 370 :1189 –1197 .